Skip to main content
OpenTrials

Clinical trial condition

Liver Diseases

Explore clinical trials studying Liver Diseases. Study availability and eligibility vary by location and protocol.

8,421 public trials 1,317 recruiting studies
Refine in advanced search Browse all conditions

Liver Diseases trial results

Completed

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations
  • Advanced Clinical Res Inst Anaheim, California, United States
  • West Coast Clinical Trials, Llc Cypress, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Elite Research Institute Miami, Florida, United States
View Trial Details
Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Scripps Clinic La Jolla, California, United States
  • CLI Los Angeles, California, United States
  • Desta Digestive Disease Medical Center San Diego, California, United States
View all 72 locations
View Trial Details
Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

NCT01016912

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Hiroshima, Japan
  • Local Institution Sapporo, Hokkaido, Japan
  • Local Institution Kawasaki-Shi, Kanagawa, Japan
  • Local Institution Suita-Shi, Osaka, Japan
View Trial Details
Completed

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

NCT01389323

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Va Long Beach Healthcare System - 11 Long Beach, California, United States
  • Axis Clinical Trials Los Angeles, California, United States
  • Greater Los Angeles Healthcare System Los Angeles, California, United States
View all 36 locations
View Trial Details
Completed

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

NCT01448044

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Scti Research Foundation San Clemente, California, United States
  • Umass Memorial Medical Center Worcester, Massachusetts, United States
  • University Gastroenterology Providence, Rhode Island, United States
  • Metropolitan Research Annandale, Virginia, United States
View all 26 locations
View Trial Details
Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Precision Research Institute, Llc San Diego, California, United States
  • Medical Associates Research Group San Diego, California, United States
  • University Of California, San Francisco/Sf General Hospital San Francisco, California, United States
View all 124 locations
View Trial Details

Related conditions